ERBB2 and breast cancer: Men and postmenopausal women with HR+/HER2 ‐ advanced BC, who received prior treatment with an AI either as (neo)‐adjuvant or for advanced diseaseRelapsed with evidence of progression within or more than 12 months from completion of (neo)‐adjuvant therapyNewly diagnosed advanced BC relapsed with documented progression on or after one line of endocrine therapy